Relapsing high grade mucoepidermoid carcinoma : Long-lasting complete response following reirradiation and EGFR blockade

Strahlentherapie und Onkologie

Volumn 188, Issue 6, 2012, Pages 518-522

  Milanovic, D ^a   Jeremic, B ^b   Kayser, G ^a   Rischke, H C ^a   Pfeiffer, J ^a   Henke, A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Institute of Lung Diseases   (Serbia)

Author keywords

Antibodies, monoclonal; Cetuximab; Neoplasms; Radiotherapy; Receptor, epidermal growth factor

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN;

ACNEIFORM RASH; ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; CANCER GRADING; CANCER RELAPSE; CASE REPORT; CELL DIFFERENTIATION; CELL INFILTRATION; DERMATITIS; DYSPHAGIA; EPITHELIUM CELL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRRADIATION; LYMPH NODE; MUCOSA INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX PAIN; POLYMERASE CHAIN REACTION; RASH; REIRRADIATION; RETREATMENT; TONGUE CARCINOMA; TREATMENT RESPONSE; XEROSTOMIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, MUCOEPIDERMOID; COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PALATE, HARD; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; SALIVARY GLAND NEOPLASMS; SALIVARY GLANDS, MINOR;

EID: 84862639918     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0096-1     Document Type: Article

References (28)

1. Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28
2. Brohl A, Steadman K, Kallakury B, Deeken JF (2010) Efficacy of combining targeted therapies cetuximab and dasatinib for resistant salivary gland carcinomas in vitro. J Clin Oncol 28:15S (abstr 5557)
3. Burdak-Rothkamm S, Rübe CE, Nguyen TP et al (2005) Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). Strahlenther Onkol 181:197-204
4. Buerger H, Gebhardt F, Schmidt H et al (2000) Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res 60:854-857 (Pubitemid 30129514)
5. Dittmann K, Mayer C, Rodemann HP (2010) Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlenther Onkol 186:1-6
6. Erovic BM, Schopper C, Pammer J et al (2010) Multimodal treatment of patients with minor salivary gland cancer in the case of recurrent disease. Head Neck 32:1167-1172
7. Gebhardt F, Bürger H, Brandt B (2000) Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations-a link between genetics and epigenetics. Histol Histopathol 15:929-936 (Pubitemid 30488572)
8. Gibbons MD, Manne U, Carroll WR et al (2001) Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 111:1373-1378 (Pubitemid 32730182)
9. Glisson BS, Blumenschein G, Francisco M et al (2005) Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 23:580S (abstr 5532)
10. Goode RK, Auclair PL, Ellis GL (1998) Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 82:1217-1224 (Pubitemid 28155381)
11. Grisanti S, Amoroso V, Buglione M et al (2008) Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature. J Med Case Reports 30:320
12. Guzzo M, Locati LD, Prott FJ et al (2010) Major and minor salivary gland tumors. Crit Rev Oncol Hematol 74:134-148
13. Hoebers F, Heemsbergen W, Moor S et al (2011) Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys 81:e111-118
14. Laurie SA, Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24:2673-2678 (Pubitemid 46622089)
15. Licitra L, Mesia R, Rivera F et al (2011) Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 22:1078-1087
16. Locati LD, Bossi P, Perrone F et al (2009) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574-578
17. Lujan B, Hakim S, Moyano S et al (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510-516
18. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139 (Pubitemid 38637993)
19. Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966-971 (Pubitemid 38221157)
20. Monteiro LS, Bento MJ, Palmeira C et al (2009) Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J Oral Pathol Med 38:508-513
21. Nance MA, Seethala RR, Wang Y et al (2008) Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer 113:2082-2089
22. Balermpas P, Hambek M, Seitz O et al (2009) Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol 185:775-781
23. Platteaux N, Dirix P, Vanstraelen B et al (2011) Outcome after re-irradiation of head and neck cancer patients. Strahlenther Onkol 187:23-31
24. Seethala RR (2011) Histologic grading and prognostic biomarkers in salivary gland carcinomas. Adv Anat Pathol 18:29-45
25. Selzer E, Liederer S, Lemaire C et al (2011) Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab. Strahlenther Onkol 187:373-377
26. Sholl LM, John Iafrate A, Chou YP et al (2007) Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol 20:1028-1035 (Pubitemid 47429204)
27. Tsuchihashi Z, Khambata-Ford S, Hanna N et al (2005) Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353:208-209 (Pubitemid 41058356)
28. Zwicker F, Roeder F, Thieke C et al (2011) IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 187:32-38